Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01092611 · ClinicalTrials.gov registry record · Phase 1

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

A Phase 1 study of AIDS, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 1
Development phase
190
Enrollment target
20
Study locations

NCT01092611: Completed Phase 1 study of AIDS, sponsored by GlaxoSmithKline.

NCT01092611 is a Phase 1 study of AIDS that has completed, run by GlaxoSmithKline. The registered enrollment target is 190 participants, below the 1,567-participant average among 13 other AIDS trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01092611, a Phase 1 study of AIDS, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 1
Development phase
190 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this long-term follow-up study is to assess the long-term health status of HIV-infected subjects who previously participated in GSK-sponsored trials evaluating the investigational HIV vaccine 732462. This study will provide additional data concerning the long-term benefits/risks associated with vaccination. No vaccine will be administered during the study period. Vaccines were administered during the primary studies.

Conditions Studied

Interventions

  • PROCEDURE Blood collection
  • BIOLOGICAL GSK HIV vaccine 732462

Study Locations (20)

Other

  • GSK Investigational Site - Bobigny
  • GSK Investigational Site - Créteil
  • GSK Investigational Site - Nantes
  • GSK Investigational Site - Paris
  • GSK Investigational Site - Paris
  • GSK Investigational Site - Paris
  • GSK Investigational Site - Paris
  • GSK Investigational Site - Paris
  • GSK Investigational Site - Paris

Florida

  • GSK Investigational Site - Fort Lauderdale
  • GSK Investigational Site - Orlando

Pennsylvania

  • GSK Investigational Site - Philadelphia
  • GSK Investigational Site - Philadelphia

California

  • GSK Investigational Site - Bakersfield

Nebraska

  • GSK Investigational Site - Omaha

New Jersey

  • GSK Investigational Site - Camden

Ohio

  • GSK Investigational Site - Columbus

Texas

  • GSK Investigational Site - Dallas

Trial Details

FieldValue
Enrollment Target 190 participants
Start Date 2010-03-22
Est. Completion 2014-05-19
Phase Phase 1
GlaxoSmithKline

1,345 total trials

What the finished NCT01092611 record still lists

NCT01092611 is an interventional study that assigns participants to a tested intervention. The registered 190 participants enrollment target is mid-sized for trials with a published cap, below the 1,567-participant average among 13 other AIDS trials with a reported enrollment target (88% lower).

The record links to 1 condition, with AIDS appearing as the primary indexed condition, and to 2 interventions - of which Blood collection is the first listed.

NCT01092611 names 20 study sites across 10 states, led by Other, Florida, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01092611 about?

NCT01092611 is a clinical study titled "Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine". The purpose of this long-term follow-up study is to assess the long-term health status of HIV-infected subjects who previously participated in GSK-sponsored trials evaluating the investigational HIV vaccine 732462. This study will provide additional data concerning the long-term benefits/risks assoc...

What is the current status of trial NCT01092611?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 190 participants. The study started on 2010-03-22. Estimated completion is 2014-05-19.

What conditions does trial NCT01092611 study?

This clinical trial studies the following conditions: AIDS.

What interventions are being tested in trial NCT01092611?

The interventions under investigation include: Blood collection (PROCEDURE), GSK HIV vaccine 732462 (BIOLOGICAL).

Who is sponsoring clinical trial NCT01092611?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01092611 being conducted?

This trial has 20 study locations across California, Florida, Nebraska, New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for AIDS

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01092611's enrollment target sits among peer trials

190 5th of 13 higher than 9 of 13 other AIDS trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other AIDS trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03257033 · 190 participants · Phase 3

    Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

  • NCT03642028 · 190 participants · Phase 4

    Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress

  • NCT04015609 · 190 participants · NA

    Psychotherapy Intervention for Latinos With Advanced Cancer

  • NCT04284397 · 190 participants · Early Phase 1

    Identification of Critical Thermal Environments for Aged Adults

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01092611, the US trial registry maintained by the National Library of Medicine. NCT01092611 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.